Coya Therapeutics Announces That Its Combination LD IL-2/GLP-1 RA Candidate (COYA 303) Demonstrated Potent Systemic and Brain Anti-Inflammatory Efficacy In Vivo
Coya Therapeutics, Inc. (COYA)
Company Research
Source: Business Wire
COYA 303 is an investigational proprietary biologic combination of low-dose (LD)-IL-2 and GLP-1 receptor agonist (RA) for subcutaneous administration with potential for treating inflammation-driven diseases like Alzheimer's Disease, and other neurodegenerative and autoimmune diseasesCOYA 303 significantly reduced peripheral pro-inflammatory cell expansion, enhanced Regulatory T Cell function, attenuated CNS inflammation, and shifted macrophages to an anti-inflammatory phenotype, compared to controlsCOYA-303 may represent a next-generation dual immunomodulatory GLP-1–based therapy uniting the Nobel Prize–recognized science of regulatory T cells (Tregs) with the emerging immune benefits of GLP-1 receptor agonists. HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, today announced results of an in vivo animal study designed to eval
Show less
Read more
Impact Snapshot
Event Time:
COYA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
COYA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
COYA alerts
High impacting Coya Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
COYA
News
- Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials Conferences [Yahoo! Finance]Yahoo! Finance
- ReAlta Life Sciences Appoints Dr. Howard Berman as Executive ChairmanBusiness Wire
- Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials ConferencesBusiness Wire
- Coya Therapeutics (NASDAQ:COYA) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- Coya Therapeutics (NASDAQ:COYA) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=COYA&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street MarketBeat
COYA
Earnings
- 11/12/25 - Miss
COYA
Sec Filings
- 11/12/25 - Form 10-Q
- 11/12/25 - Form 8-K
- 10/27/25 - Form 8-K
- COYA's page on the SEC website